← Definitive Healthcare Corp.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Net loss | ($51.2m) | ($61.3m) | ($22.3m) | ($289.6m) | ($591.4m) | ($199.3m) | — | |
| Depreciation and amortization | $1.2m | $1.8m | $2.2m | $2.0m | $2.2m | $3.3m | $55.5m | |
| Amortization of intangible assets | $58.4m | $58.2m | $54.7m | $49.8m | $49.4m | $52.8m | — | |
| Amortization of deferred contract costs | $1.7m | $4.8m | $8.8m | $13.0m | $15.4m | $15.9m | — | |
| Amortization of debt issuance costs | $2.1m | $1.7m | $702k | $702k | $702k | $519k | — | |
| Deferred income taxes | $0 | $682k | ($17.3m) | ($18.7m) | ($42.7m) | ($10.9m) | ($11.0m) | |
| Goodwill impairment charges | — | $0 | $0 | $287.4m | $688.9m | $196.1m | — | |
| Accounts receivable | ($8.3m) | ($10.7m) | ($13.2m) | $811k | $5.7m | $1.4m | $4.3m | |
| Accounts payable, accrued expenses and other liabilities | $3.0m | $1.1m | $358k | $1.3m | ($5.5m) | ($1.1m) | ($3.9m) | |
| Capital expenditures included in accounts payable and accrued expenses and other liabilities | $3.4m | $654k | $1.2m | $47k | $6.9m | $4.5m | ($12.2m) | |
| Deferred revenue | $12.1m | $23.0m | $12.7m | ($6.6m) | ($5.0m) | $5.9m | — | |
| Unpaid equity offering costs included in accrued expenses | $0 | $1.3m | $0 | $0 | — | — | — | |
| Prepaid expenses and other assets | ($709k) | ($3.7m) | ($127k) | ($7.2m) | ($7.8m) | ($2.2m) | — | |
| Purchases of property, equipment and other assets | ($1.4m) | ($6.7m) | ($8.3m) | ($3.0m) | ($12.3m) | ($16.7m) | — | |
| Net cash provided by operating activities | $23.2m |
$25.2m
+8.59%
|
$35.6m
+41.12%
|
$41.2m
+15.77%
|
$58.2m
+41.29%
|
$53.8m
-7.59%
|
$39.3m
-26.97%
|
|
| Purchases of short-term investments | $0 | $0 | ($338.0m) | ($259.2m) | ($304.3m) | ($64.1m) | — | |
| Maturities of short-term investments | $0 | $0 | $153.7m | $275.4m | $303.8m | $234.7m | — | |
| Cash paid for acquisitions and investments, net of cash acquired | ($22.5m) | ($40.0m) | ($56.3m) | ($45.0m) | ($13.5m) | $0 | — | |
| Net cash paid for acquisitions | $22.5m | $0 | $56.3m | $45.0m | $13.5m | $0 | — | |
| Net cash provided by (used in) investing activities | ($23.9m) | ($46.7m) | ($248.9m) | ($31.8m) | ($26.4m) | $153.9m | $64.1m | |
| (Recovery of) provision for bad debt expense | — | — | $1.3m | $1.4m | $947k | ($232k) | — | |
| Loss on partial extinguishment of debt | — | — | — | $0 | $0 | $507k | — | |
| Payments of debt issuance costs | ($225k) | ($3.5m) | $0 | $0 | $0 | ($1.7m) | — | |
| Repurchases of Class A common stock | — | — | $0 | $0 | ($22.4m) | ($49.5m) | — | |
| Taxes paid related to net share settlement of equity awards | $0 | $0 | ($4.1m) | ($4.4m) | ($7.5m) | ($4.9m) | — | |
| Net cash used in financing activities | $16.7m |
$384.4m
+2207.85%
|
($26.7m)
-106.95%
|
($25.6m)
+4.17%
|
($56.7m)
-121.81%
|
($150.8m)
-165.71%
|
($52.0m)
+65.54%
|
|
| Net increase (decrease) in cash and cash equivalents | $16.0m | $362.9m | ($240.0m) | ($16.2m) | ($25.0m) | $56.9m | — | |
| Cash and cash equivalents, beginning of year | $24.8m | $387.5m | $146.9m | $131.0m | $105.4m | $163.6m | — | |
| Effect of exchange rate changes on cash and cash equivalents | $146k | ($129k) | ($544k) | $218k | ($636k) | $1.4m | $123k | |
| Additional Supplementary Disclosures | ||||||||
| Additional Supplementary Disclosures | ||||||||
| Equity-based compensation | $1.7m | $10.0m | $36.4m | $48.7m | $38.1m | $29.1m | — | |
| Write-off of deferred offering costs | — | — | — | $0 | $0 | $467k | — | |
| Non-cash restructuring charges | — | — | $1.0m | $155k | $1.2m | $595k | — | |
| TRA remeasurement | $0 | $0 | ($9.4m) | ($23.5m) | ($76.9m) | ($21.7m) | — | |
| Changes in fair value of contingent consideration | $2.6m | $3.8m | $1.2m | $302k | ($1.8m) | ($4.0m) | — | |
| Deferred contract costs | ($7.7m) | ($14.4m) | ($15.3m) | ($18.8m) | ($12.8m) | ($13.4m) | — | |
| Contingent consideration | ($2.6m) | $0 | ($1.0m) | ($7.8m) | ($602k) | $0 | — | |
| Repayments of term loans | — | — | ($6.9m) | ($8.6m) | ($13.8m) | ($252.8m) | — | |
| Proceeds from term loan | $0 | $275.0m | $0 | $0 | $0 | $175.0m | — | |
| Payments of contingent consideration | $0 | ($1.5m) | ($1.1m) | $0 | ($1.0m) | $0 | — | |
| Payments under TRA | — | $0 | $0 | ($246k) | ($7.0m) | ($13.8m) | — | |
| Payments of equity offering issuance costs | $0 | ($11.7m) | ($1.7m) | ($30k) | $0 | $0 | — | |
| Member distributions | ($2.9m) | ($8.1m) | ($12.9m) | ($12.3m) | ($5.1m) | ($3.1m) | — | |
| Interest | $26.0m | $29.6m | $10.4m | $14.5m | $14.2m | $10.8m | $11.0m | |
| Income taxes | $0 | $13k | $0 | $136k | $0 | $833k | — | |
| Net assets acquired, net of cash acquired | $43.6m | $0 | $97.3m | $52.7m | $13.7m | $0 | — | |
| Working capital adjustment receivable | — | $0 | $0 | $145k | ($145k) | $0 | — |